Publications internationales
Nous mettons ici à votre disposition une sélection de publications scientifiques en rapport avec l'immunothérapie IOZK.
Vous pouvez effectuer une sélection par type de tumeur et par méthode à l'aide des filtres ou saisir des termes de recherche.
Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
Newcastle disease virus: a promising agent for tumour immunotherapy
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
Cell-type-specific innate immune response to oncolytic Newcastle disease virus
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
Bugs and drugs: oncolytic virotherapy in combination with chemotherapy
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation
Recent clinical experience with oncolytic viruses
Immunotherapies for non-small-cell lung cancer and mesothelioma
Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study
Old and new facts about hyperthermia-induced modulations of the immune system
Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.
Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.
The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.